Relay Therapeutics Reports Strong Q4/FY25 Results, Extends Cash Runway to 2029, and Outlines Key 2026 Clinical Milestones

summarizeSummary

Relay Therapeutics reported improved Q4 and full year 2025 financial results, extending its cash runway into 2029, and announced multiple upcoming clinical data readouts for its lead drug candidate, zovegalisib.

check_boxKey Events

• Extended Cash Runway into 2029

  The company reported $554.5 million in cash, cash equivalents, and investments as of December 31, 2025, and expects this to fund operations into 2029, significantly de-risking its financial outlook.

• Multiple Clinical Milestones for Zovegalisib

  Relay Therapeutics anticipates announcing initial Phase 1 data for zovegalisib in PIK3CA-driven vascular anomalies in 1H 2026 and breast cancer triplet data and frontline Phase 3 plans in 2026. This follows the recent Breakthrough Therapy Designation for zovegalisib.

• Near-Term Data Presentation at ESMO TAT

  Initial Phase 1/2 data of zovegalisib + fulvestrant at the Phase 3 dose in CDK4/6-experienced breast cancer patients will be presented at the ESMO TAT Congress on March 16, 2026.

• Improved Financial Performance

  The company reported a reduced net loss of $54.9 million for Q4 2025 (vs. $76.0 million in Q4 2024) and $276.5 million for full year 2025 (vs. $337.7 million in full year 2024), alongside increased revenue and decreased R&D and G&A expenses.

auto_awesomeAnalysis

Relay Therapeutics announced robust financial results for Q4 and full year 2025, highlighted by a significant extension of its cash runway into 2029. This strong financial position, with $554.5 million in cash, cash equivalents, and investments, substantially de-risks the company from near-term financing needs. The filing also outlines a pivotal year ahead with multiple clinical milestones for zovegalisib, including initial Phase 1 data in PIK3CA-driven vascular anomalies and breast cancer triplet data, building on the recent Breakthrough Therapy Designation. The upcoming presentation of Phase 1/2 breast cancer data at ESMO TAT on March 16, 2026, provides a near-term catalyst for investors, especially as the stock is trading near its 52-week high.